Global Biosimilar Contract Manufacturing Market Forecast 2026–2035
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Biosimilar Contract Manufacturing Market In 2026 And What Value Is Projected For 2030?
The biosimilar contract manufacturing market has experienced significant expansion in recent years. It is anticipated to expand from $9.94 billion in 2025 to $11.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.7%. This historic growth can be attributed to several factors, including the expiration of reference biologic patents, the early initiation of biosimilar development programs, the broadening of contract manufacturing partnerships, enhanced regulatory guidance on biosimilars, and an increase in the prevalence of chronic diseases.
The biosimilar contract manufacturing market is projected for significant expansion over the coming years. This market is anticipated to reach $20.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.4%. Factors contributing to this growth during the forecast period include the increasing number of biosimilar approvals worldwide, the growing demand to lower biologic treatment expenses, the expansion of biosimilar development pipelines, rising investments in large-scale production facilities, and improvements in process optimization technologies. Key trends expected in the forecast period encompass a surge in outsourced biosimilar production, an increasing need for economical production platforms, a heightened focus on analytical and quality assurance services, the broadening of mammalian cell-based manufacturing, and a stronger emphasis on adherence to regulatory standards.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30215&type=smp
What Drivers Are Influencing The Biosimilar Contract Manufacturing Market?
The increasing incidence of diabetes is projected to fuel the expansion of the biosimilar contract manufacturing market. Diabetes prevalence signifies the proportion of a population currently living with the condition, indicating a continuous need for treatment and lifelong therapeutic demand. This rise in diabetes cases stems from more sedentary lifestyles and unhealthy eating habits, contributing to obesity, insulin resistance, and a greater occurrence of type 2 diabetes. Biosimilar contract manufacturing aids in managing diabetes by facilitating the economical and large-scale production of biosimilar insulin and associated biologics. This process guarantees consistent quality and adherence to regulations, thereby making advanced treatments more widely available and affordable for patients, ultimately improving worldwide access to critical diabetes care. For example, data from June 2024, provided by the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023. This represented an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the expanding prevalence of diabetes is a key factor propelling the growth of the biosimilar contract manufacturing market.
What Are The Key Segments Of The Biosimilar Contract Manufacturing Market?
The biosimilar contract manufacturing market covered in this report is segmented –
1) By Product Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, Other Product Types
2) By Service Type: Process Development, Analytical And Quality Control, Fill And Finish Operations, Packaging, Other Service Types
3) By Source: Mammalian, Non-mammalian
4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
5) By End-Use: Pharmaceutical Companies, Biotech Companies
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Insulin: Rapid Acting Insulin, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Premixed Insulin
3) By Erythropoietin: Alpha Erythropoietin, Beta Erythropoietin, Darbepoetin Alfa, Continuous Erythropoietin Receptor Activators
4) By Granulocyte Colony-Stimulating Factor: Filgrastim, Pegfilgrastim, Lenograstim, Long Acting Granulocyte Colony-Stimulating Factor
5) By Other Product Types: Interferons, Interleukins, Fusion Proteins, Enzyme Therapeutics, Hormonal Biologics
What Key Trends Are Influencing The Development Of The Biosimilar Contract Manufacturing Market?
Leading companies in the biosimilar contract manufacturing sector are concentrating on establishing advanced production facilities, particularly mirrored single-use plants, to enhance technology transfer, accelerate scale-up processes, and bolster commercial reliability. These mirrored single-use plants consist of identical production suites that operate with disposable bioprocess equipment and integrated digital systems, facilitating swift changeovers, maintaining consistent quality across various locations, and minimizing contamination risks. For example, in September 2025, Rezon Bio, a contract development and manufacturing organization (CDMO) based in Poland, inaugurated two single-use biomanufacturing sites with mirrored capabilities, offering services from cell line development up to commercial GMP supply. This strategy supports more rapid technology transfer and adaptable scale-up for biosimilars with decreased operational downtime, while simultaneously improving batch-to-batch uniformity through standardized suites, incorporated analytics, and automated logistics. Moreover, it reduces the total cost of ownership for sponsors by lessening cleaning validation demands, shortening development and manufacturing durations, and mitigating expansion-related risks.
Who Are The Leading Companies Operating In The Biosimilar Contract Manufacturing Market?
Major companies operating in the biosimilar contract manufacturing market are Thermo Fisher Scientific Inc., Biocon Limited, Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Laboratorios Farmacéuticos Rovi S.A., Vetter Pharma-Fertigung GmbH & Co. KG, National Resilience Inc., Porton Pharma Solutions Co. Ltd., Syngene International Limited, Rentschler Biopharma SE, Boehringer Ingelheim International GmbH, Enzene Biosciences Ltd., Prestige Biologics Co. Ltd., Mabion S.A., HALIX B.V., BioConnection B.V., BioCina Pty Ltd, Mycenax Biotech Inc., Polpharma Biologics S.A.
Read the full biosimilar contract manufacturing market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Biosimilar Contract Manufacturing Market?
North America was the largest region in the biosimilar contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Biosimilar Contract Manufacturing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30215&type=smp
Browse Through More Reports Similar to the Global Biosimilar Contract Manufacturing Market 2026, By The Business Research Company
Biopharmaceuticals Contract Manufacturing Market Report 2026
Medical Device Contract Manufacturing Market Report 2026
Food Contract Manufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/food-contract-manufacturing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
